INMED PHARMACEUTICALS INC. Legal Fees
INMED PHARMACEUTICALS INC. (INM) reported Legal Fees of $316.98 thousand for the 12-month period ending 2025-06-30, per its S-4 filed 2026-07-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LegalFees · last filed 2026-07-02
- INMED PHARMACEUTICALS INC. legal fees for the quarter ending 2024-12-31 was $194.43K, a 66.25% increase year-over-year.
- INMED PHARMACEUTICALS INC. legal fees for the quarter ending 2024-06-30 was $29.64K.
- INMED PHARMACEUTICALS INC. legal fees for the quarter ending 2024-03-31 was $66.00K.
- INMED PHARMACEUTICALS INC. legal fees for the quarter ending 2023-12-31 was $116.95K.
- INMED PHARMACEUTICALS INC. legal fees for fiscal 2023 was $634.21K, a 217.10% increase from fiscal 2022.
- INMED PHARMACEUTICALS INC. legal fees for fiscal 2022 was $200.00K.
| Period end | Legal Fees 3 month | Legal Fees 5 month | Legal Fees 6 month | Legal Fees 7 month | Legal Fees 9 month | Legal Fees 11 month | Legal Fees 12 month | Legal Fees 14 month |
|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | $316.98K S-4 · filed 2026-07-02 | |||||||
| 2025-02-10 | $316.98K 10-Q · filed 2025-05-12 | |||||||
| 2024-12-31 | $194.43K 10-Q · filed 2025-02-12 | $316.98K 10-Q · filed 2025-02-12 | ||||||
| 2024-06-30 | $29.64K derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | $95.64K derived: sum of 2 quarters · filed 2026-07-02 | $212.59K derived: sum of 3 quarters · filed 2026-07-02 | $226.79K S-4 · filed 2026-07-02 | ||||
| 2024-03-31 | $66.00K 10-Q · filed 2025-05-12 | $182.95K derived: sum of 2 quarters · filed 2025-05-12 | $197.16K 10-Q · filed 2025-05-12 | |||||
| 2023-12-31 | $116.95K 10-Q · filed 2025-02-12 | $131.15K 10-Q · filed 2025-02-12 | ||||||
| 2023-06-30 | $634.21K 10-K · filed 2023-09-29 | |||||||
| 2023-03-31 | $580.76K 10-Q · filed 2023-05-15 | |||||||
| 2022-12-31 | $491.75K 10-Q · filed 2023-02-17 | |||||||
| 2022-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | $345.94K 10-K · filed 2023-09-29 | $0.00 derived: sum of 2 quarters · filed 2022-09-23 | $200.00K 10-K · filed 2022-09-23 | ||||
| 2022-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-13 | $200.00K 10-Q · filed 2022-05-13 | ||||||
| 2021-12-31 | $200.00K 10-Q · filed 2022-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |